Quantum-Si incorporated
HealthcareNASDAQ:QSI · NASDAQ Global Market
-$0.03 today
Vol 3.27M · Avg 5.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-46.0%
avg -55.4%
ROIC
-43.4%
avg -54.5%
ROA
-41.3%
avg -50.4%
Analysis
ROA is currently the strongest return metric at -41.3% versus its period average of -50.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeffrey Alan Hawkins | President, Chief Executive Officer & Director | $1.18M | — | 48 | $3.69M | 1.87% |
Jeffry R. Keyes | Chief Financial Officer & Treasurer | $756,849.00 | — | 53 | $251,185.00 | 0.13% |
John S. Vieceli | Chief Product Officer | $605,002.00 | — | 49 | $251,185.00 | 0.13% |
Christian Lapointe | General Counsel & Corporate Secretary | $490,000.00 | — | 54 | $1.20M | 0.61% |
Jonathan Rothberg | Founder & Executive Director | $50,000.00 | — | 62 | $251,185.00 | 0.13% |
Lindsay Thompson | Chief Human Resources Officer | — | — | — | — | — |
Todd Rearick | Chief Technology Officer | — | — | — | $681,521.00 | 0.34% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$564,250.45
Sells
31
$729,297.44
Net Sentiment
$165,046.99
Net selling
Most Active
Keyes Jeffry R.
8 transactions
1–10 of 33
Analysis
Insiders reported 2 buys worth $564,250.45 and 31 sells worth $729,297.44 over the last 12 months. That adds up to net selling of $165,046.99. Keyes Jeffry R. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +96.2% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +96.2% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages QSI?
Quantum-Si incorporated (QSI) lists 7 active executives. The top listed executive is Jeffry R. Keyes, Chief Financial Officer & Treasurer.
Are QSI insiders buying or selling?
Recent insider activity shows net buying of $68.38M.
Explore More
Continue the stock analysis
Jump to another research area for this company.